Skip to content

Effectivity of P1821, a Novel Tongue Strengthening and Endurance Enhancing Speech Flow Exercise

Effectivity of P1821, a Novel Tongue Strengthening and Endurance Enhancing Speech Flow Exercise

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07719582
Enrollment
100
Registered
2026-07-22
Start date
2028-01-01
Completion date
2030-01-01
Last updated
2026-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankyloglossia, Impairment of Speech, Slurred Speech

Keywords

Tongue-strengthening self-exercises (TSsE), Tongue strength, Home-based exercise, Self-exercise

Brief summary

The P1821 initiative constitutes an innovative intervention specifically engineered to enhance tongue muscular strength and endurance. The primary objective of this research study is to ascertain whether the integration of a proactive tongue strengthening exercise regimen, utilizing a Non-Significant Risk (NSR) Device, contributes to an observable improvement in speech fluency.

Detailed description

P1821 specifically targets the muscles in the tongue. These areas are part of the tongue's movable section, known for their great flexibility and ability to perform complex movements. The tongue plays a crucial role in speech production. Weakness in its muscles can lead to difficulties in speaking clearly and distinctly. The tongue is a highly mobile group of muscles, richly supplied with blood and nerves. The tongue's remarkable ability to move in all directions stems from the unique arrangement of its muscle fibers, which is unlike any other muscle in the body. These fibers run in three dimensions: From front to back, from the sides to the middle, and from top to bottom. This unique structure allows the tongue to perform a variety of movements, including: Getting longer and shorter. The tongue is the only muscle in the body that can be actively lengthened, not just shortened. When the vertical and horizontal fibers contract simultaneously, the tongue becomes narrower and longer, enabling it to be extended. Changing its position: Additional muscles can alter the tongue's overall position by pulling it from the front (from the lower jaw), from below and behind (from the hyoid bone), and from above and behind (from the base of the skull).

Interventions

DEVICEP1821

The P1821 intervention is distinguished by its independence from pharmaceutical agents and electronic devices. Its foundational mechanism is predicated exclusively on the physiological principles of muscle resistance training, thereby offering a non-pharmacological and non-invasive therapeutic approach.

Sponsors

Dream Video LLC
Lead SponsorOTHER
Dream Holdings Research
CollaboratorUNKNOWN

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

All study participants will get the same intervention.

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Can read and write * Willing and able to follow the requirements of the protocol

Exclusion criteria

* Previously seen and treated by speech and language pathologist for dysphagia or dysarthria for non-head and neck cancer causes * Medical instability, restlessness, or other factors that would compromise data acquisition

Design outcomes

Primary

MeasureTime frameDescription
P1821From enrollment to the end of treatment at 2 weeks.The primary key performance indicator will be the proportion of study participants who demonstrate statistically significant and measurable improvements in their speaking ability following the completion of the two-week treatment protocol within P1821. This metric is crucial for evaluating the efficacy of the intervention and will be assessed through standardized linguistic and speech pathology evaluations.

Countries

United States

Contacts

CONTACTMatthew Quitto II
dream@dreamholdingsllc.com917-342-2895

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 23, 2026